Cardinal Health reported robust second-quarter fiscal 2026 results, with revenues hitting $65.63 billion and net income rising to $467 million, up from $401 million the previous year. Adjusted earnings per share reached $2.63, prompting the company to revise its full-year earnings guidance to between $10.15 and $10.35. The firm also continued its aggressive share repurchase strategy, completing $1.48 billion in buybacks, while its Pharmaceutical and Specialty Solutions segment saw an increase in revenue and profit margins.
“Cardinal Health CAH · is positioning itself as · foundational layer of the U.S. healthcare system · true”
“Cardinal Health · trades at a forward price-to-earnings ratio of · 16.93 · true”
“Cardinal Health · currently carries · a Zacks Rank #2 (Buy) · true”
“Cardinal Health · approved · quarterly dividend · $0.5107 per share”
“Cardinal Health · reported · adjusted earnings · $2.63 per share”
“Cardinal Health · reported · revenue · $65.63 billion”
“Cardinal Health · raises fiscal year 2026 non-GAAP EPS guidance · $10.15 to $10.35”
“Cardinal Health · completed · annual baseline share repurchase · $750 million”
“Cardinal Health · is raising fiscal year 2026 guidance · non-GAAP diluted EPS · $10.15 to $10.35”
“Cardinal Health · completed · $375 million accelerated share repurchase program”
“Cardinal Health · earned · Great Place to Work Certification · six countries”
“Cardinal Health · raised · fiscal year 2026 guidance for non-GAAP diluted EPS · $10.15 to $10.35”